Related Articles

• Clinical significance of circulating microparticles in Ph- myeloproliferative neoplasms
• Prevalence of the Janus kinase 2 V617F mutation in Philadelphia‑negative myeloproliferative neoplasms in a Portuguese population
• Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1‑negative myeloproliferative neoplasms
• pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms
• A drug targeting 5‑lipoxygenase enhances the activity of a JAK2 inhibitor in CD34⁺ bone marrow cells from patients with JAK2V617F‑positive polycythemia vera <em>in vitro</em>